Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07608159 | Neoadjuvant SF-SBRT Plus Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC. | PHASE3 | NOT YET_RECRUITING | 201 | — | — | May 1, 2026 | May 1, 2030 | May 29, 2026 | - | — |
| Arm | Type | Description |
|---|---|---|
| neoadjuvant SF-SBRT followed by toripalimab and platinum-based chemotherapy | EXPERIMENTAL | neoadjuvant SF-SBRT followed by toripalimab and platinum-based chemotherapy |
| toripalimab and platinum-based chemotherapy | ACTIVE_COMPARATOR | toripalimab and platinum-based chemotherapy |
| Name | Type | Description |
|---|---|---|
| Stereotactic body radiotherapy (SBRT) | RADIATION | spatially fractionated stereotactic body radiotherapy |
| neoadjuvant immunotherapy | DRUG | Toripalimab IV (dose 240mg) Q3W |
| Neoadjuvant Chemotherapy | DRUG | Squamous cell carcinoma: Paclitaxel (175mg/m²) or Docetaxel (60-75 mg/m²) or Nab-paclitaxel (260mg/m²) plus Carboplatin (AUC=5)/Cisplatin (75 mg/m²) (to be determined by researchers); Non-squamous cell carcinoma: Pemetrexed (500mg/m²) plus Carboplatin/Cisplatin (to be determined by researchers) |
Inclusion Criteria: * Male or female participants aged 18 to 75 years; * Eastern Cooperative Oncology Group performance status of 0 or 1; * Previously untreated, pathologically confirmed, resectable or potentially -resectable stage II, IIIA, or IIIB (N2) non-small cell lung cancer according to the ...